Drug Insights

A Complete Guide to Searching Nitroglycerin on Synapse

27 March 2024
2 min read

Nitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983. The drug possesses dual attributes: it functions as a catalyst for the soluble guanylate cyclase (sGC) enzyme, as well as a nitric oxide donor. Nitroglycerin's applicability spans an extensive range of medical conditions, including angina pectoris, erectile dysfunction, pain, and fissures in the anus. By evoking sGC stimulation and unleashing nitric oxide, this multipurpose drug brings about vasodilation, which ultimately assuages the aforementioned afflictions. Click on the image below to begin the exploration journey of Nitroglycerin through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Ivonescimab Shows Promise Against Brain Metastases in NSCLC
Latest Hotspot
3 min read
Ivonescimab Shows Promise Against Brain Metastases in NSCLC
27 March 2024
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024.
Read →
AstraZeneca JMC Reports on RXFP1 Agonist AZD5462
Hot Spotlight
5 min read
AstraZeneca JMC Reports on RXFP1 Agonist AZD5462
27 March 2024
Recently, AstraZeneca reported in detail the discovery process of the RXFP1 agonist AZD5462, currently in Phase II clinical trials, in two consecutive articles published in the top-tier journal JMC (Journal of Medicinal Chemistry).
Read →
Results of Phase III Study of Enspryng in Patients with Generalized Myasthenia Gravis
Latest Hotspot
3 min read
Results of Phase III Study of Enspryng in Patients with Generalized Myasthenia Gravis
27 March 2024
Chugai Pharmaceutical revealed Phase III LUMINESCE trial results for their drug Enspryng (satralizumab).
Read →
Using Synapse for Your Atomoxetine Research: An Easy Guide
Drug Insights
2 min read
Using Synapse for Your Atomoxetine Research: An Easy Guide
27 March 2024
Atomoxetine, a diminutive molecule drug concocted by Eli Lilly, procured its inaugural medical approval in 2002.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.